抽象的な

Treatment of cancer by targeted therapy

Tingbo Huang

Targeted therapeutic medications have replaced conventional chemotherapy agents as the goto cancer treatments due to their advantages in efficacy and safety. A growing number of smallmolecule targeted medications have been created for the treatment of malignancies since the US Food and Drug Administration (FDA) authorized the first tyrosine kinase inhibitor imagine to go on sale in 2001. By the end of 2020, both the National Medical Products Administration (NMPA) of China and the US FDA will have approved 89 small-molecule targeted anticancer medications. Despite significant advancements, drug resistance and low response rates are remain major obstacles for small-molecule focused anti-cancer treatments. We reviewed all small-molecule targeted anti-cancer medications in-depth in order to better encourage the development of these medications.